Phospho-TGFBR2 (Tyr284) Antibody - #AF8191
(3)
(9)
| Product: | Phospho-TGFBR2 (Tyr284) Antibody |
| Catalog: | AF8191 |
| Description: | Rabbit polyclonal antibody to Phospho-TGFBR2 (Tyr284) |
| Application: | WB IHC |
| Reactivity: | Human, Mouse, Rat |
| Prediction: | Pig, Bovine, Horse, Rabbit, Dog, Chicken, Xenopus |
| Mol.Wt.: | 70~85kD; 65kD(Calculated). |
| Uniprot: | P37173 |
| RRID: | AB_2840253 |
Related Downloads
Protocols
Product Info
*The optimal dilutions should be determined by the end user.
*Tips:
WB: For western blot detection of denatured protein samples. IHC: For immunohistochemical detection of paraffin sections (IHC-p) or frozen sections (IHC-f) of tissue samples. IF/ICC: For immunofluorescence detection of cell samples. ELISA(peptide): For ELISA detection of antigenic peptide.
Cite Format: Affinity Biosciences Cat# AF8191, RRID:AB_2840253.
Fold/Unfold
AAT3; FAA3; LDS1B; LDS2; LDS2B; MFS2; RIIC; TAAD2; TbetaR II; TbetaR-II; TGF beta receptor type 2; TGF beta receptor type II; TGF beta receptor type IIB; TGF beta type II receptor; TGF-beta receptor type II; TGF-beta receptor type-2; TGF-beta type II receptor; TGF-beta-R2; TGFB R2; TGFbeta - RII; TGFbeta RII; Tgfbr2; TGFR-2; TGFR2_HUMAN; Transforming growth factor beta receptor II; Transforming growth factor beta receptor type II; Transforming growth factor beta receptor type IIC; Transforming growth factor, beta receptor II (70/80kDa); transforming growth factor, beta receptor II alpha; transforming growth factor, beta receptor II beta; transforming growth factor, beta receptor II delta; transforming growth factor, beta receptor II epsilon; transforming growth factor, beta receptor II gamma; Transforming growth factor-beta receptor type II;
Immunogens
- P37173 TGFR2_HUMAN:
- Protein BLAST With
- NCBI/
- ExPASy/
- Uniprot
MGRGLLRGLWPLHIVLWTRIASTIPPHVQKSVNNDMIVTDNNGAVKFPQLCKFCDVRFSTCDNQKSCMSNCSITSICEKPQEVCVAVWRKNDENITLETVCHDPKLPYHDFILEDAASPKCIMKEKKKPGETFFMCSCSSDECNDNIIFSEEYNTSNPDLLLVIFQVTGISLLPPLGVAISVIIIFYCYRVNRQQKLSSTWETGKTRKLMEFSEHCAIILEDDRSDISSTCANNINHNTELLPIELDTLVGKGRFAEVYKAKLKQNTSEQFETVAVKIFPYEEYASWKTEKDIFSDINLKHENILQFLTAEERKTELGKQYWLITAFHAKGNLQEYLTRHVISWEDLRKLGSSLARGIAHLHSDHTPCGRPKMPIVHRDLKSSNILVKNDLTCCLCDFGLSLRLDPTLSVDDLANSGQVGTARYMAPEVLESRMNLENVESFKQTDVYSMALVLWEMTSRCNAVGEVKDYEPPFGSKVREHPCVESMKDNVLRDRGRPEIPSFWLNHQGIQMVCETLTECWDHDPEARLTAQCVAERFSELEHLDRLSGRSCSEEKIPEDGSLNTTK
Predictions
Score>80(red) has high confidence and is suggested to be used for WB detection. *The prediction model is mainly based on the alignment of immunogen sequences, the results are for reference only, not as the basis of quality assurance.
High(score>80) Medium(80>score>50) Low(score<50) No confidence
PTMs - P37173 As Substrate
| Site | PTM Type | Enzyme | Source |
|---|---|---|---|
| T39 | O-Glycosylation | Uniprot | |
| K205 | Ubiquitination | Uniprot | |
| K208 | Ubiquitination | Uniprot | |
| S213 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| Y259 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| K260 | Ubiquitination | Uniprot | |
| K264 | Ubiquitination | Uniprot | |
| Y284 | Phosphorylation | P12931 (SRC) | Uniprot |
| K291 | Ubiquitination | Uniprot | |
| K300 | Ubiquitination | Uniprot | |
| Y336 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| S352 | Phosphorylation | Uniprot | |
| K381 | Ubiquitination | Uniprot | |
| S409 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| S416 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| Y424 | Phosphorylation | P37173 (TGFBR2) | Uniprot |
| T445 | Phosphorylation | Uniprot | |
| Y470 | Phosphorylation | Uniprot | |
| K477 | Ubiquitination | Uniprot | |
| S486 | Phosphorylation | Uniprot | |
| K488 | Ubiquitination | Uniprot | |
| S548 | Phosphorylation | Uniprot | |
| S551 | Phosphorylation | Uniprot | |
| S553 | Phosphorylation | Uniprot | |
| K556 | Ubiquitination | Uniprot | |
| S562 | Phosphorylation | Uniprot | |
| T566 | Phosphorylation | Uniprot |
PTMs - P37173 As Enzyme
| Substrate | Site | Source |
|---|---|---|
| P17813 (ENG) | S634 | Uniprot |
| P17813 (ENG) | S635 | Uniprot |
| P36897 (TGFBR1) | S165 | Uniprot |
| P36897-1 (TGFBR1) | S172 | Uniprot |
| P36897 (TGFBR1) | T176 | Uniprot |
| P36897 (TGFBR1) | T185 | Uniprot |
| P36897 (TGFBR1) | T186 | Uniprot |
| P36897 (TGFBR1) | S187 | Uniprot |
| P36897 (TGFBR1) | S189 | Uniprot |
| P36897 (TGFBR1) | S191 | Uniprot |
| P37173 (TGFBR2) | S213 | Uniprot |
| P37173-2 (TGFBR2) | S238 | Uniprot |
| P37173 (TGFBR2) | Y259 | Uniprot |
| P37173 (TGFBR2) | Y336 | Uniprot |
| P37173-1 (TGFBR2) | S409 | Uniprot |
| P37173 (TGFBR2) | S416 | Uniprot |
| P37173 (TGFBR2) | Y424 | Uniprot |
| P37173-2 (TGFBR2) | S434 | Uniprot |
| P37173-2 (TGFBR2) | S441 | Uniprot |
| Q03167 (TGFBR3) | T843 | Uniprot |
| Q9NPB6 (PARD6A) | S345 | Uniprot |
Research Backgrounds
Transmembrane serine/threonine kinase forming with the TGF-beta type I serine/threonine kinase receptor, TGFBR1, the non-promiscuous receptor for the TGF-beta cytokines TGFB1, TGFB2 and TGFB3. Transduces the TGFB1, TGFB2 and TGFB3 signal from the cell surface to the cytoplasm and is thus regulating a plethora of physiological and pathological processes including cell cycle arrest in epithelial and hematopoietic cells, control of mesenchymal cell proliferation and differentiation, wound healing, extracellular matrix production, immunosuppression and carcinogenesis. The formation of the receptor complex composed of 2 TGFBR1 and 2 TGFBR2 molecules symmetrically bound to the cytokine dimer results in the phosphorylation and the activation of TGFRB1 by the constitutively active TGFBR2. Activated TGFBR1 phosphorylates SMAD2 which dissociates from the receptor and interacts with SMAD4. The SMAD2-SMAD4 complex is subsequently translocated to the nucleus where it modulates the transcription of the TGF-beta-regulated genes. This constitutes the canonical SMAD-dependent TGF-beta signaling cascade. Also involved in non-canonical, SMAD-independent TGF-beta signaling pathways.
Phosphorylated on a Ser/Thr residue in the cytoplasmic domain.
Cell membrane>Single-pass type I membrane protein. Membrane raft.
Homodimer. Heterohexamer; TGFB1, TGFB2 and TGFB3 homodimeric ligands assemble a functional receptor composed of two TGFBR1 and TGFBR2 heterodimers to form a ligand-receptor heterohexamer. The respective affinity of TGFRB1 and TGFRB2 for the ligands may modulate the kinetics of assembly of the receptor and may explain the different biological activities of TGFB1, TGFB2 and TGFB3. Interacts with DAXX. Interacts with TCTEX1D4. Interacts with ZFYVE9; ZFYVE9 recruits SMAD2 and SMAD3 to the TGF-beta receptor. Interacts with and is activated by SCUBE3; this interaction does not affect TGFB1-binding to TGFBR2. Interacts with VPS39; this interaction is independent of the receptor kinase activity and of the presence of TGF-beta. Interacts with CLU.
Belongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. TGFB receptor subfamily.
Research Fields
· Cellular Processes > Transport and catabolism > Endocytosis. (View pathway)
· Cellular Processes > Cell growth and death > Cellular senescence. (View pathway)
· Cellular Processes > Cellular community - eukaryotes > Adherens junction. (View pathway)
· Environmental Information Processing > Signal transduction > MAPK signaling pathway. (View pathway)
· Environmental Information Processing > Signaling molecules and interaction > Cytokine-cytokine receptor interaction. (View pathway)
· Environmental Information Processing > Signal transduction > FoxO signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > TGF-beta signaling pathway. (View pathway)
· Environmental Information Processing > Signal transduction > Hippo signaling pathway. (View pathway)
· Human Diseases > Infectious diseases: Parasitic > Chagas disease (American trypanosomiasis).
· Human Diseases > Infectious diseases: Viral > HTLV-I infection.
· Human Diseases > Cancers: Overview > Pathways in cancer. (View pathway)
· Human Diseases > Cancers: Overview > Transcriptional misregulation in cancer.
· Human Diseases > Cancers: Specific types > Colorectal cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Pancreatic cancer. (View pathway)
· Human Diseases > Cancers: Specific types > Chronic myeloid leukemia. (View pathway)
· Human Diseases > Cancers: Specific types > Hepatocellular carcinoma. (View pathway)
· Human Diseases > Cancers: Specific types > Gastric cancer. (View pathway)
· Organismal Systems > Development > Osteoclast differentiation. (View pathway)
· Organismal Systems > Immune system > Th17 cell differentiation. (View pathway)
· Organismal Systems > Endocrine system > Relaxin signaling pathway.
References
Application: WB Species: Mouse Sample: OS cells
Application: WB Species: mouse Sample:
Application: WB Species: mouse Sample: CFs
Application: WB Species: rat Sample: heart
Restrictive clause
Affinity Biosciences tests all products strictly. Citations are provided as a resource for additional applications that have not been validated by Affinity Biosciences. Please choose the appropriate format for each application and consult Materials and Methods sections for additional details about the use of any product in these publications.
For Research Use Only.
Not for use in diagnostic or therapeutic procedures. Not for resale. Not for distribution without written consent. Affinity Biosciences will not be held responsible for patent infringement or other violations that may occur with the use of our products. Affinity Biosciences, Affinity Biosciences Logo and all other trademarks are the property of Affinity Biosciences LTD.